Science & Technology

Selecting the ideal contract development and manufacturing organization (CDMO) is undergoing a fundamental shift. Historically, decisions were dictated by straightforward factors like facility scale, basic technical capabilities, and initial costs.

Today, macroeconomic volatility, supply chain disruptions, and the rise of complex modalities like bioconjugates demand a more sophisticated approach. Modern evaluations prioritize operational resilience and true capacity access over sheer reactor volume. Furthermore, sponsors are leveraging digital tools, process analytical technology, and AI to ensure predictability and speed without sacrificing quality.

Ultimately, evaluating CDMOs has expanded into assessing true strategic alignment—seeking transparent, adaptable partners capable of proactively mitigating downstream manufacturing risks and supporting long-term portfolio pipelines.

For full access to this content, please click the download button below